Anti-immunoglobulin E therapy: is it a valid option for the management of chronic rhinosinusitis with nasal polyposis?

被引:3
作者
Wahba, Ashraf A. [1 ]
Abdelfattah, Ahmed M. [2 ]
机构
[1] Al Azhar Univ, Damietta Branch, Fac Med, Dept Otorhinolaryngol, Dumyat, Egypt
[2] Al Azhar Univ, Fac Med, Dept Otorhinolaryngol, Cairo, Egypt
关键词
chronic rhinosinusitis with nasal polyposis; omalizumab; recurrence rate; surgery-sparing effect; ANTI-IGE; OMALIZUMAB; ASTHMA; RHINITIS;
D O I
10.4103/ejo.ejo_19_19
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objectives To evaluate the efficacy of omalizumab (OMA) therapy for patients with chronic rhinosinusitis with nasal polyposis as a sole therapeutic line versus traditional therapy. Patients and methods Eighty-six patients were randomly divided into two equal groups: study patients received OMA [0.016 mg/kg/immunoglobulin E (IgE) (IU/mI)] therapy only and control patients received conventional therapy. All patients completed a questionnaire to determine the total subjective score (TSS), who underwent rigid nasal endoscopy for endoscopic scoring according to the Lund-Kennedy scoring system, had paranasal sinuses computed tomographic (CT) imaging for scoring according to the Lund-Mackay scale, and estimation of pretreatment serum IgE levels. Study outcomes included the therapeutic effect determined as more than 50% decrease of TSS with improvement on endoscopic findings, recurrence rate, and frequency of decision; shift to surgery or repeat the trial of OMA therapy. Results Serum IgE level positively correlated with TSS and endoscopic and CT scores. Seventeen patients had successful response without recurrence with significantly lower TSS in the study versus control patients. Twenty-seven patients had recurrence after primary successful outcome with significantly lower TSS in study than control patients and significantly longer duration till recurrence with OMA than conventional therapy. Forty-two patients showed no response to the first session of therapy. Nineteen study patients with recurrent manifestations received a second session of OMA therapy; 11 had successful response, five patients had rerecurrence, and three patients failed to respond. Surgery-sparing effect is significantly higher with OMA than conventional therapy (46.5 vs. 18.6%). Endoscopic and CT scores of total patients, at the end of follow-up, were nonsignificantly lower in control while they were significantly lower in the study group. Conclusion OMA significantly superiorly improved the outcome of conservative treatment of chronic rhinosinusitis with nasal polyposis than conventional with higher surgery-sparing rate. The second session of OMA minimized the recurrence rate of manifestations.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 29 条
  • [1] [Anonymous], 1997, Otolaryngol Head Neck Surg, V117, pS1
  • [2] Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
    Bachert, Claus
    Sousa, Ana R.
    Lund, Valerie J.
    Scadding, Glenis K.
    Gevaert, Philippe
    Nasser, Shuaib
    Durham, Stephen R.
    Cornet, Marjolein E.
    Kariyawasam, Harsha H.
    Gilbert, Jane
    Austin, Daren
    Maxwell, Aoife C.
    Marshall, Richard P.
    Fokkens, Wytske J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (04) : 1024 - +
  • [3] Advances in rhinitis and rhinosinusitis in 2015
    Bachert, Claus
    Gevaert, Elien
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (05) : 1277 - 1283
  • [4] Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis
    Bachert, Claus
    Zhang, Luo
    Gevaert, Phillippe
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (06) : 1431 - 1440
  • [5] Bakhshaee Mehdi, 2014, Iran J Otorhinolaryngol, V26, P245
  • [6] Correlation of histopathology and symptoms in allergic and non-allergic patients with chronic rhinosinusitis
    Baudoin, Tomislav
    Kalogjera, Livije
    Geber, Goran
    Grgic, Marko
    Cupic, Hrvoje
    Tiljak, Mirjana Kujundzic
    [J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2008, 265 (06) : 657 - 661
  • [7] Bidder T, 2018, RHINOLOGY, V56, P42, DOI [10.4193/Rhin17.139, 10.4193/Rhino17.139]
  • [8] Cavaliere C, 2018, J BIOL REG HOMEOS AG, V32, P167
  • [9] Impact of omalizumab therapy on medication requirements for chronic rhinosinusitis
    Chandra, Rakesh K.
    Clavenna, Matthew
    Samuelson, Madeleine
    Tanner, S. Bobo
    Turner, Justin H.
    [J]. INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2016, 6 (05) : 472 - 477
  • [10] Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis
    Clavenna, Matthew J.
    Turner, Justin H.
    Samuelson, Madeleine
    Tanner, S. Bobo
    Duncavage, James
    Chandra, Rakesh K.
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2016, 37 (01) : 23 - 26